[The role of slow-release 5-fluorouracil implantation in treatment of unresectable pancreatic cancer].

Objective: To study the role of slow-release 5-fluorouracil implantation in treatment of unresectable pancreatic cancer.
Methods: 85 cases of untreated patients with locally advanced pancreatic cancer (LAPC) were randomized into two groups: Trial group: slow-release 5-fluorouracil implantation (50 patients) and control group (35 patients). Observing the objective tumor response, clinical benefit response, toxicity, complications and survival of patients of the two groups.
Results: In the trial group the overall response rate (PR + NC) was 76.0%, and the clinical benefit response rate was 52.0%. No toxicity was observed. Pancreatic fistula occurred in 2 patients. The median survival time of the two groups was 9.0 months and 4.0 months, respectively. The survival rates of 6- and 12-month were 56.8% vs. 31.4% and 22.9% vs. 2.9% in the two groups, respectively (P = 0.012).
Conclusion: Slow-release 5-fluorouracil implantation is a simple, safe and effective method in treatment of LAPC.